Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 4, 2011, Pages 1603-1608

  Yeh, Hsin Hsien ^a   Ogawa, Kazuma ^a,b   Balatoni, Julius ^a   Mukhapadhyay, Uday ^a   Pal, Asutosh ^a   Gonzalez Lepera, Carlos ^a   Shavrin, Aleksandr ^a   Soghomonyan, Suren ^a   Flores II, Leo ^a   Young, Daniel ^a   Volgin, Andrei Y ^a   Najjar, Amer M ^a   Krasnykh, Victor ^a   Tong, William ^a   Alauddin, Mian M ^a   Gelovani, Juri G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

Activation mutation; Epidermal growth factor receptor; Positron emission tomography

Indexed keywords

4 [(3 IODOPHENYL)AMINO] 7 [2 [2 [2 [2 [2 [2 (FLUOROETHOXY) ETHOXY]ETHOXY]ETHOXY]ETHOXY]ETHOXY]QUINAZOLINE 6 YL ACRYLAMIDE F 18; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG SENSITIVITY; GENE MUTATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

AMINO ACID SUBSTITUTION; ANIMALS; BINDING, COMPETITIVE; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; MOLECULAR IMAGING; MUTANT PROTEINS; MUTATION; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOMOGRAPHY, X-RAY COMPUTED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 79952126083     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1010744108     Document Type: Article

References (67)

1. World Health Organization (2009) Cancer. Fact sheet No.297. Available at http://www.who.int/mediacentre/factsheets/fs297/en/index.html. Accessed December 30, 2010.
2. ACS (2009) Cancer Reference Information. Available at http://www.cancer.org/Cancer/LungCancer-Non-SmallCell/DetailedGuide/ non-small-cell-lung-cancer-key-statistics=. Accessed December 30, 2010.
3. Pirker R, Filipits M (2009) Targeted therapies in lung cancer. Curr Pharm Des 15:188-206.
4. Fukuoka M, et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21:2237-2246. (Pubitemid 46621858)
5. Kris MG, et al. (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149-2158. (Pubitemid 37432975)
6. Paez JG, et al. (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500. (Pubitemid 38720929)
7. Huang CM, et al. (2004) Epidermal growth factor receptor (EGFR) gene Bsr I polymorphism is associated with systemic lupus erythematosus. Lupus 13:773-776.
8. Thatcher N, et al. (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537. (Pubitemid 41540110)
9. Shepherd FA, Tsao MS (2006) Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy. J Clin Oncol 24:1219-1220. (Pubitemid 46638822)
10. Riely GJ, et al. (2006) Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12:839-844. (Pubitemid 43259866)
11. Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169-181.
12. Lynch TJ, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139. (Pubitemid 38637993)
13. Pao W, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306-13311. (Pubitemid 39209661)
14. Mu XL, Li LY, Zhang XT, Wang SL, Wang MZ (2004) Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: Experience from a compassionate-use programme. BMC Cancer 4:51-59.
15. Bell DW, et al. (2005) Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23:8081-8092. (Pubitemid 46657411)
16. Cappuzzo F, et al. (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643-655. (Pubitemid 40812628)
17. Chou TY, et al. (2005) Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 11:3750-3757.
18. Cortes-Funes H, et al. (2005) Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol 16:1081-1086. (Pubitemid 41418309)
19. Eberhard DA, et al. (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900-5909.
20. Han SW, et al. (2005) Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy resistant non-small cell lung cancer. Int J Cancer 113:109-115.
21. Kim JC, et al. (2005) Correlation of HER1/EGFR expression and degree of radiosensitizing effect of the HER1/EGFR-tyrosine kinase inhibitor erlotinib. Indian J Biochem Biophys 42:358-365.
22. Kondo M, et al. (2005) Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery. Lung Cancer 50:385-391.
23. Mitsudomi T, et al. (2005) Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23:2513-2520. (Pubitemid 47050841)
24. Takano T, et al. (2005) Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23:6829-6837.
25. Taron M, et al. (2005) Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 11:5878-5885. (Pubitemid 41170316)
26. Tomizawa Y, et al. (2005) Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res 11:6816-6822. (Pubitemid 41428736)
27. Tsao MS, et al. (2005) Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353:133-144.
28. Zhang XT, et al. (2005) The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Ann Oncol 16:1334-1342.
29. Shih HC, Hsiao YP, Wu MF, Yang JH (2006) Gefitinib-induced acute generalized exanthematous pustulosis in two patients with advanced non-small-cell lung cancer. Br J Dermatol 155:1101-1102.
30. Uramoto H, et al. (2006) Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. Lung Cancer 51:71-77.
31. Kobayashi S, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786-792.
32. Pao W, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73.
33. Kosaka T, et al. (2006) Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12:5764-5769. (Pubitemid 44629607)
34. Gazdar AF (2009) Activating and resistance mutations of EGFR in non-small-cell lung cancer: Role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28 (Suppl 1):S24-S31.
35. Maheswaran S, et al. (2008) Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359:366-377.
36. Mishani E, Abourbeh G (2007) Cancer molecular imaging: Radionuclide-based biomarkers of the epidermal growth factor receptor (EGFR). Curr Top Med Chem 7:1755-1772. (Pubitemid 350130995)
37. Mishani E, Hagooly A (2009) Strategies for molecular imaging of epidermal growth factor receptor tyrosine kinase in cancer. J Nucl Med 50:1199-1202.
38. Bonasera TA, et al. (2001) Potential (18)F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase. Nucl Med Biol 28:359-374. (Pubitemid 32520994)
39. Ortu G, et al. (2002) Labeled EGFr-TK irreversible inhibitor (ML03): In vitro and in vivo properties, potential as PET biomarker for cancer and feasibility as anticancer drug. Int J Cancer 101:360-370.
40. Mishani E, et al. (2004) Novel carbon-11 labeled 4-dimethylamino-but-2- enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: Potential PET bioprobes for molecular imaging of EGFR-positive tumors. Nucl Med Biol 31:469-476.
41. Abourbeh G, et al. (2007) Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors. Nucl Med Biol 34:55-70. (Pubitemid 46038157)
42. Dissoki S, et al. (2007) The effect of the [18F]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline-6-YL]-amide moiety - an EGFR putative irreversible inhibitor. Appl Radiat Isot 65:1140-1151. (Pubitemid 47333371)
43. Pal A, et al. (2006) Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol 8:262-277. (Pubitemid 44446020)
44. Su H, et al. (2008) Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging 35:1089-1099.
45. 11C-PD153035. Chin Med J (Engl) 120:960-964.
46. 11C]-labeled erlotinib: A micro-PET study on mice with lung tumor xenografts. Cancer Res 69:873-878.
47. Pantaleo MA, et al. (2010) Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET. Mol Imaging Biol 12:616-625.
48. 11C-PD153035 in humans. J Nucl Med 50:303-308.
49. Gelovani JG (2008) Molecular imaging of epidermal growth factor receptor expression-activity at the kinase level in tumors with positron emission tomography. Cancer Metastasis Rev 27:645-653.
50. Cappuzzo F, et al. (2003) Gefitinib in pretreated non-small-cell lung cancer (NSCLC): Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 21:2658-2663. (Pubitemid 46606308)
51. Hirsch FR, et al. (2005) Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study. J Clin Oncol 23:6838-6845.
52. Tracy S, et al. (2004) Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 64:7241-7244. (Pubitemid 39372059)
53. Mukohara T, et al. (2005) Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 97:1185-1194. (Pubitemid 41258224)
54. Yun CH, et al. (2007) Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11:217-227.
55. Guo A, et al. (2008) Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA 105:692-697. (Pubitemid 351171770)
56. Liu Y, Shah K, Yang F, Witucki L, Shokat KM (1998) Engineering Src family protein kinases with unnatural nucleotide specificity. Chem Biol 5:91-101. (Pubitemid 28199138)
57. Gorre ME, et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880. (Pubitemid 32743979)
58. Blencke S, Ullrich A, Daub H (2003) Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J Biol Chem 278:15435-15440. (Pubitemid 36799884)
59. Kwak EL, et al. (2005) Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102:7665-7670. (Pubitemid 40741028)
60. Pao W, et al. (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2:e17.
61. McDermott U, et al. (2007) Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci USA 104:19936-19941.
62. Zhou W, et al. (2009) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462:1070-1074.
63. Pal ABJ, et al. (2010) Radiosynthesis and initial in vitro evaluation of [(18)F]F-PEG (6)-IPQA-A novel PET radiotracer for imaging EGFR expression-activity in lung carcinomas. Mol Imaging Biol, September 22 [Epub ahead of print].
64. Arao T, et al. (2004) Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res 64:9101-9104. (Pubitemid 39665524)
65. Noro R, et al. (2006) Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation. BMC Cancer 6:277-289.
66. Hosaka T, et al. (2007) Mutant epidermal growth factor receptor undergoes less protein degradation due to diminished binding to c-Cbl. Anticancer Res 27:2253-2263. (Pubitemid 47228061)
67. Najjar AM, et al. (2009) Molecular-genetic PET imaging using an HSV1-tk mutant reporter gene with enhanced specificity to acycloguanosine nucleoside analogs. J Nucl Med 50:409-416.